Stergios A. Pοlyzos

16.6k total citations · 1 hit paper
301 papers, 10.9k citations indexed

About

Stergios A. Pοlyzos is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Stergios A. Pοlyzos has authored 301 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Epidemiology, 103 papers in Endocrinology, Diabetes and Metabolism and 77 papers in Surgery. Recurrent topics in Stergios A. Pοlyzos's work include Liver Disease Diagnosis and Treatment (108 papers), Bone health and treatments (60 papers) and Diet, Metabolism, and Disease (46 papers). Stergios A. Pοlyzos is often cited by papers focused on Liver Disease Diagnosis and Treatment (108 papers), Bone health and treatments (60 papers) and Diet, Metabolism, and Disease (46 papers). Stergios A. Pοlyzos collaborates with scholars based in Greece, United States and Switzerland. Stergios A. Pοlyzos's co-authors include Christos S. Mantzoros, Jannis Kountouras, Athanasios D. Anastasilakis, Јannis Kountouras, Christos Zavos, Polyzois Makras, Georgia Deretzi, Dimitrios G. Goulis, Nikolaos Perakakis and Zoe Efstathiadou and has published in prestigious journals such as SHILAP Revista de lepidopterología, Endocrine Reviews and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Stergios A. Pοlyzos

293 papers receiving 10.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics

2018 849 citations Stergios A. Pοlyzos, Јannis Kountouras et al. profile →

Peers

Countries citing papers authored by Stergios A. Pοlyzos

Since Specialization

Citations

This map shows the geographic impact of Stergios A. Pοlyzos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stergios A. Pοlyzos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stergios A. Pοlyzos more than expected).

Fields of papers citing papers by Stergios A. Pοlyzos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stergios A. Pοlyzos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stergios A. Pοlyzos. The network helps show where Stergios A. Pοlyzos may publish in the future.

Co-authorship network of co-authors of Stergios A. Pοlyzos

This figure shows the co-authorship network connecting the top 25 collaborators of Stergios A. Pοlyzos. A scholar is included among the top collaborators of Stergios A. Pοlyzos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stergios A. Pοlyzos. Stergios A. Pοlyzos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review 2025 ·Current Obesity Reports ·(unknown), Stergios A. Pοlyzos	2
2	Outdoor environment and obesity: A review of current evidence 2024 ·SHILAP Revista de lepidopterología ·(unknown), Stergios A. Pοlyzos	4
3	MASLD Is Associated With an Increased Long‐Term Risk of Atrial Fibrillation: An Updated Systematic Review and Meta‐Analysis 2024 ·Liver International ·Alessandro Mantovani, (unknown), (unknown), (unknown), (unknown), Stefano Bonapace, Salvatore Petta, Stergios A. Pοlyzos, Christopher D. Byrne, Giovanni Targher	10
4	Circulating lipoprotein(a) in patients with nonalcoholic fatty liver disease: a systematic review and meta‐analysis 2024 ·Journal of Gastroenterology and Hepatology ·(unknown), (unknown), (unknown), Dimitrios G. Goulis, Stergios A. Pοlyzos	1
5	Effects of Combined Low-Dose Spironolactone Plus Vitamin E versus Vitamin E Monotherapy on Lipidomic Profile in Non-Alcoholic Fatty Liver Disease: A Post Hoc Analysis of a Randomized Controlled Trial 2024 ·Journal of Clinical Medicine ·(unknown), (unknown), Helen Gika, (unknown), Kali Makedou, (unknown), Јannis Kountouras, Stergios A. Pοlyzos	2
6	Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease 2023 ·Therapeutics and Clinical Risk Management ·(unknown), Christos S. Mantzoros, Stergios A. Pοlyzos	30
7	An association study of the PNPLA3 I148M polymorphism (rs738409) with serum lipids in patients with dyslipidemia 2023 ·SHILAP Revista de lepidopterología ·(unknown), Evangelia Makri, Stergios A. Pοlyzos, (unknown), Dimitrios Agapakis, Georgios Germanidis, Antonis Goulas	2
8	Controlling the Impact of Helicobacter pylori-Related Hyperhomocysteinemia on Neurodegeneration 2023 ·Medicina ·Jannis Kountouras, Michael Doulberis, Apostolis Papaefthymiou, Stergios A. Pοlyzos, Christos Zavos, Evangelos Kazakos, (unknown), (unknown), (unknown), Marina Boziki, Elisabeth Vardaka	15
9	Association between Helicobacter pylori Infection and Nasal Polyps: A Systematic Review and Meta-Analysis 2023 ·Microorganisms ·Michael Doulberis, Јannis Kountouras, (unknown), Christian M. Meerwein, Stergios A. Pοlyzos, Hasan Kulaksiz, Michael H. Chapman, Gerhard Rogler, (unknown), (unknown), (unknown), Evangelos Kazakos, (unknown), Christos Liatsos, Apostolis Papaefthymiou	8
10	Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease 2022 ·Current Obesity Reports ·Stergios A. Pοlyzos, Dimitrios G. Goulis, Όλγα Γιουλεμέ, Georgios Germanidis, Antonis Goulas	26
11	Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study 2022 ·Clinical Nutrition ·Matina Kouvari, Stergios A. Pοlyzos, Christina Chrysohoou, John Skoumas, Christos Pitsavos, Demosthenes B. Panagiotakos, Christos S. Mantzoros	26
12	Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation 2021 ·Calcified Tissue International ·Athanasios D. Anastasilakis, Stergios A. Pοlyzos, Maria P. Yavropoulou, Natasha M. Appelman‐Dijkstra, (unknown), (unknown), Αθανάσιος Παπαθεοδώρου, Polyzois Makras	9
13	Hypophosphatasia 2021 ·Journal of Clinical Medicine ·Symeon Tournis, Maria P. Yavropoulou, Stergios A. Pοlyzos, Artemis Doulgeraki	24
14	Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough 2020 ·Journal of Clinical Densitometry ·Athanasios D. Anastasilakis, George Trovas, Alexia Balanika, Stergios A. Pοlyzos, Polyzois Makras, Symeon Tournis	9
15	Similar late effects of a 7-week orthodox religious fasting and a time restricted eating pattern on anthropometric and metabolic profiles of overweight adults 2020 ·International Journal of Food Sciences and Nutrition ·Spyridon Ν. Karras, Theocharis Koufakis, (unknown), Stergios A. Pοlyzos, (unknown), (unknown), Pantelis Zebekakis, Kali Makedou, Kalliopi Kotsa	24
16	Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis 2019 ·European Journal of Pharmacology ·(unknown), (unknown), Stergios A. Pοlyzos	40
17	Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass. 2019 ·PubMed ·Athanasios D. Anastasilakis, Stergios A. Pοlyzos, Polyzois Makras, Martina Rauner, (unknown), Gerhard Hawa, Elena Tsourdi, Maria P. Yavropoulou, (unknown), Evangelos Terpos	0
18	Clinical Features of 24 Patients With Rebound‐Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases 2017 ·Journal of Bone and Mineral Research ·Athanasios D. Anastasilakis, Stergios A. Pοlyzos, Polyzois Makras, Bérengère Aubry‐Rozier, (unknown), Olivier Lamy	241
19	Vaspin, resistin, retinol-binding protein-4, interleukin-1α and interleukin-6 in patients with nonalcoholic fatty liver disease. 2017 ·SHILAP Revista de lepidopterología ·Stergios A. Pοlyzos, Јannis Kountouras, (unknown), (unknown), Christos Zavos, Panagiotis Katsinelos	21
20	Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis 2013 ·Clinical Endocrinology ·Polyzois Makras, Stergios A. Pοlyzos, Αθανάσιος Παπαθεοδώρου, Panagiotis Kokkoris, (unknown), Athanasios D. Anastasilakis	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact